BLUEPRINT MEDICINES CORP (BPMC) Stock Price, Quote, News and Overview
NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD
BPMC Quote, Performance and Key Statistics
86.09
+0.28 (+0.33%)
The current stock price of BPMC is 86.09 USD. In the past month the price decreased by -5.1%. In the past year, price decreased by -7.43%.
BPMC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 23.03 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About BPMC
Company Profile
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jeffrey W. Albers
Employees: 638
Company Website: https://www.blueprintmedicines.com/
Investor Relations: https://ir.blueprintmedicines.com
Phone: 16173747580
BLUEPRINT MEDICINES CORP / BPMC FAQ
What is the stock price of BLUEPRINT MEDICINES CORP today?
The current stock price of BPMC is 86.09 USD. The price increased by 0.33% in the last trading session.
What is the ticker symbol for BLUEPRINT MEDICINES CORP stock?
The exchange symbol of BLUEPRINT MEDICINES CORP is BPMC and it is listed on the Nasdaq exchange.
On which exchange is BPMC stock listed?
BPMC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BLUEPRINT MEDICINES CORP stock?
29 analysts have analysed BPMC and the average price target is 130.03 USD. This implies a price increase of 51.03% is expected in the next year compared to the current price of 86.09. Check the BLUEPRINT MEDICINES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BLUEPRINT MEDICINES CORP worth?
BLUEPRINT MEDICINES CORP (BPMC) has a market capitalization of 5.50B USD. This makes BPMC a Mid Cap stock.
How many employees does BLUEPRINT MEDICINES CORP have?
BLUEPRINT MEDICINES CORP (BPMC) currently has 638 employees.
What are the support and resistance levels for BLUEPRINT MEDICINES CORP (BPMC) stock?
BLUEPRINT MEDICINES CORP (BPMC) has a support level at 80.84 and a resistance level at 95.27. Check the full technical report for a detailed analysis of BPMC support and resistance levels.
Is BLUEPRINT MEDICINES CORP (BPMC) expected to grow?
The Revenue of BLUEPRINT MEDICINES CORP (BPMC) is expected to grow by 42.93% in the next year. Check the estimates tab for more information on the BPMC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BLUEPRINT MEDICINES CORP (BPMC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BPMC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BPMC, evaluating the profitability, health, valuation and growth aspects
- BLUEPRINT MEDICINES CORP (BPMC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BLUEPRINT MEDICINES CORP (BPMC) Sales and EPS estimates to see what analysts future expectations are.
- BLUEPRINT MEDICINES CORP (BPMC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BLUEPRINT MEDICINES CORP (BPMC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BLUEPRINT MEDICINES CORP (BPMC) Stock Chart to make your own analysis
- BLUEPRINT MEDICINES CORP (BPMC) Latest news and press-releases to stay up to date.
Does BLUEPRINT MEDICINES CORP (BPMC) stock pay dividends?
BPMC does not pay a dividend.
When does BLUEPRINT MEDICINES CORP (BPMC) report earnings?
BLUEPRINT MEDICINES CORP (BPMC) will report earnings on 2025-05-01, before the market open.
What is the Price/Earnings (PE) ratio of BLUEPRINT MEDICINES CORP (BPMC)?
BLUEPRINT MEDICINES CORP (BPMC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.8).
What is the Short Interest ratio of BLUEPRINT MEDICINES CORP (BPMC) stock?
The outstanding short interest for BLUEPRINT MEDICINES CORP (BPMC) is 7.49% of its float. Check the ownership tab for more information on the BPMC short interest.
BPMC Technical Analysis
BPMC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BPMC. Both the profitability and financial health of BPMC have multiple concerns.
BPMC Financial Highlights
Over the last trailing twelve months BPMC reported a non-GAAP Earnings per Share(EPS) of -3.8. The EPS increased by 54.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.69% | ||
| ROE | -22.46% | ||
| Debt/Equity | 1.15 |
BPMC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to BPMC. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of 68.69% and a revenue growth 42.93% for BPMC